Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

g of conducting clinical trials of AT2220 and ERT combination therapy; (ii) statements regarding the timing and goals of discussions with U.S. and EU regulatory authorities on the Phase 3 study and regulatory pathway for Amigal; (iii) statements on the goals, progress and timing of preclinical studies in Parkinson's disease and other research efforts aimed at evaluating disease targets in neurodegenerative and other genetic disorders; (iv) statements on the range of "cash burn" for Amicus in 2008, the need to raise additional capital in 2008 and the trends for incurring research and development expense in 2008; and (v) statements regarding expected milestone and research reimbursement payments from Shire. These forward-looking statements are based on the current estimates and assumptions of the management of Amicus as of the date of this press release and the conference call and are subject to risks, changes in circumstances, assumptions and uncertainties and other factors that may cause the actual results of Amicus to be materially different from those reflected in the forward-looking statements. Important factors that may cause actual results to differ materially from those indicated by forward-looking statements include, among others:

-- the potential that results of clinical or preclinical studies indicate

that product candidates are unsafe or ineffective,

-- our dependence on third parties in the conduct of our clinical studies,

-- a change in strategy by our collaboration partners,

-- delays or failure to achieve final agreement with regulatory

authorities on the design of phase 3 program for Amigal and the

regulatory pathway for approval of Amigal,

-- delays or failure to achieve regulatory approvals for our products,

-- risks of relying on third party manufacturers for the supply of our

product candidates,

-- our or licensors' inability to obtain, maintain and successfully<
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/26/2014)... 26, 2014 The report "Data ... Network Security Equipment, WAN Optimization Appliances]: Global Advancements, ... the data center networking market into various segments ... The report also identifies the factors driving this ... it along with the future roadmaps. , Browse ...
(Date:10/25/2014)... 25, 2014 The report “Adipic ... by Geography - Global Trends & Forecast to ... respect to market drivers, opportunities, and trends in ... and 27 figures spread through 217 slides and ... Trends & Forecast to 2019”., http://www.marketsandmarkets.com/Market-Reports/adipic-acid-269.html , ...
(Date:10/25/2014)... New York, NY (PRWEB) October 23, 2014 ... today announced the winners for the 2014 BioProcess ... collaborations, business strategies, social corporate responsibility and technology ... better, more effective treatments to a global patient ... recognized by their peers during a very entertaining ...
(Date:10/25/2014)... (PRWEB) October 24, 2014 DuPont ... plans to more than double the acreage contracted ... geographies supplying its soybean crush facility in Salisbury, ... this program will target several markets including foodservice ... with good performance. , For the 2015 growing ...
Breaking Biology Technology:Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 2Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 3Data Center Networking Market by Ethernet Switches, SAN & Routers Worth $21.85 Billion by 2018 - New Report by MarketsandMarkets 4Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 2Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 3Adipic Acid Market Estimated to Grow $7,539.2 Million by 2019 - Report by MarketsandMarkets 4BioProcess International Announces Winners of the 2014 BioProcess International Awards 2BioProcess International Announces Winners of the 2014 BioProcess International Awards 3BioProcess International Announces Winners of the 2014 BioProcess International Awards 4BioProcess International Announces Winners of the 2014 BioProcess International Awards 5DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 2DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 3DuPont Pioneer, Perdue AgriBusiness Announce Plans to Double Acreage for the 2015 Plenish® High Oleic Soybean Program 4
... amounts are in U.S. dollars, QUEBEC CITY, May ... TSX: AEZ), a global biopharmaceutical company focused on,endocrinology and ... quarter ended March 31, 2008., First Quarter ... second efficacy trial of the Phase ...
... Calif., May 6 Finesse Solutions, LLC,Santa ... control solutions for,life sciences process applications, announced ... of Software. Basil brings over 19 years ... a focus on,implementing high efficiency engineering, resource ...
... Genta,Incorporated (OTC Bulletin Board: GNTA) announced today ... Regulatory Authority (FINRA, formerly,the NASD) has cleared a ... stock on the Over-the-Counter Bulletin Board (OTCBB). As ... for the Company,s,common stock will begin on Wednesday, ...
Cached Biology Technology:AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 2AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 3AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 4AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 5AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 6AEterna Zentaris Reports First Quarter 2008 Financial and Operating Results 7Basil Zimmo Joins Finesse Solutions as Vice-President of Software 2Genta Announces Transfer of its Common Stock to the OTC Bulletin Board 2Genta Announces Transfer of its Common Stock to the OTC Bulletin Board 3
(Date:10/29/2014)... a large cohort of kidney cancer patients in Europe ... -- and reveals an apparent link between exposure to ... Romania. , The research, by an international team led ... Innovation Centre in Montreal, underscores the importance of investigating ... found in plants of the Aristolochia genus, also has ...
(Date:10/28/2014)... (NIH) announced awards to expand the Office of ... for Advancing Translational Sciences (ORDR-NCATS) collaborative Rare Diseases ... physician scientists at 22 consortia will work with ... and investigate new treatments for patients with rare ... million in fiscal 2014 funding from NIH. , ...
(Date:10/28/2014)... and juices are associated with a lower risk of ... University of East Anglia (UEA). , Research published ... and flavanones (both subclasses of dietary flavonoids) significantly decrease ... cause of cancer death among women. , The ... aged between 25 and 55 for more than three ...
Breaking Biology News(10 mins):Study sheds light on genetic architecture of kidney cancer 2Study sheds light on genetic architecture of kidney cancer 3NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 2NIH's ORDR-NCATS RDCRN & NICHD awards U54 cooperative agreement for natural history study 3Tea and citrus products could lower ovarian cancer risk, new UEA research finds 2
... WASHINGTON Synthetic biology promises to enable cheap, lifesaving ... suffer from malaria, and to create innovative biofuels that ... the science and its applications are raising questions: ... purposely changing the definition of what is life? ...
... Carolina, there are five strange looking "patches" cleared out ... circles carved by aliens. , They,re actually budding longleaf ... St. Louis and their collaborators at North Carolina State ... Washington have created these ecological patches with the help ...
... French . Plant researchers from ... announced a major breakthrough in a developmental process called ... reversal of what is called epigenetic silencing in plants. ... better understanding of gene regulation in the continuing quest ...
Cached Biology News:Synthetic biology: Is ethics a showstopper? 2Study on wildlife corridors shows how they work over time 2Study on wildlife corridors shows how they work over time 3Study on wildlife corridors shows how they work over time 4Plants display 'molecular amnesia' 2Plants display 'molecular amnesia' 3
odz, odd Oz/ten-m homolog 1 [Source:RefSeq_peptide;Acc:NP_055068] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Rabbit polyclonal to NIRF ( Abpromise for all tested applications). Antigen: Synthetic peptide derived from residues 186-235 of human NIRF. Entrez Gene ID: 115426 Swiss Protein ID: Q96PU...
Rabbit polyclonal to ZNF261 ( Abpromise for all tested applications). entrezGeneID: 9203 SwissProtID: Q14202...
sTNF-receptor I Polyclonal Antibody 100 ug affinity purified rabbit anti-human sTNF-receptor I polyclonal antibody. Performs well in WB/Elisa/Neutralization....
Biology Products: